149 related articles for article (PubMed ID: 35610365)
21. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
[TBL] [Abstract][Full Text] [Related]
22. Improved discrimination of prostate cancer and benign prostatic hyperplasia by means of the quotient of free and total PSA.
Weckermann D; Maassen C; Wawroschek F; Harzmann R
Int Urol Nephrol; 1999; 31(3):351-9. PubMed ID: 10672955
[TBL] [Abstract][Full Text] [Related]
23. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes.
Margel D; Urbach DR; Lipscombe LL; Bell CM; Kulkarni G; Austin PC; Fleshner N
J Clin Oncol; 2013 Sep; 31(25):3069-75. PubMed ID: 23918942
[TBL] [Abstract][Full Text] [Related]
24. Adult body size, sexual history and adolescent sexual development, may predict risk of developing prostate cancer: Results from the New South Wales Lifestyle and Evaluation of Risk Study (CLEAR).
Nair-Shalliker V; Yap S; Nunez C; Egger S; Rodger J; Patel MI; O'Connell DL; Sitas F; Armstrong BK; Smith DP
Int J Cancer; 2017 Feb; 140(3):565-574. PubMed ID: 27741552
[TBL] [Abstract][Full Text] [Related]
25. Prescription rates for drugs used in treatment of benign prostatic hyperplasia and erectile dysfunction before and after prostate cancer diagnosis.
Duun-Henriksen AK; Dehlendorff C; Røder MA; Skriver C; Pottegård A; Friis S; Brasso K; Larsen SB
Acta Oncol; 2022 Aug; 61(8):931-938. PubMed ID: 35666094
[TBL] [Abstract][Full Text] [Related]
26. Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database.
Allott EH; Abern MR; Gerber L; Keto CJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Moorman PG; Freedland SJ
Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):391-7. PubMed ID: 24100644
[TBL] [Abstract][Full Text] [Related]
27. Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management.
Nguyen PL; Chen MH; Catalona WJ; Alexander BM; Roehl KA; Loeb S; D'Amico AV
Cancer; 2008 Dec; 113(11):3146-52. PubMed ID: 18932254
[TBL] [Abstract][Full Text] [Related]
28. The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening.
Antunes AA; Srougi M; Dall'oglio MF; Vicentini F; Paranhos M; Freire GC
J Sex Med; 2008 Jul; 5(7):1702-7. PubMed ID: 18194186
[TBL] [Abstract][Full Text] [Related]
29. Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50-69 years with PSA ≥3 ng/ml.
Chandra Engel J; Palsdottir T; Aly M; Egevad L; Grönberg H; Eklund M; Nordström T
Scand J Urol; 2020 Feb; 54(1):1-6. PubMed ID: 31876229
[No Abstract] [Full Text] [Related]
30. [Usefulness of the percentage of free prostatic specific antigen in the differential diagnosis between benign prostatic hyperplasia and prostate cancer].
Gaspar MJ; Arribas I; Hontoria JM; Bokobo P; Coca C; Angulo JC
Med Clin (Barc); 2000 Sep; 115(9):332-6. PubMed ID: 11093893
[TBL] [Abstract][Full Text] [Related]
31. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
32. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
Collin SM; Metcalfe C; Donovan J; Lane JA; Davis M; Neal D; Hamdy F; Martin RM
BJU Int; 2008 Nov; 102(10):1400-6. PubMed ID: 18540932
[TBL] [Abstract][Full Text] [Related]
33. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer.
Hammarsten J; Högstedt B
Blood Press; 2004; 13(1):47-55. PubMed ID: 15083641
[TBL] [Abstract][Full Text] [Related]
34. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.
Roehrborn CG
Int J Impot Res; 2008 Dec; 20 Suppl 3():S19-26. PubMed ID: 19002120
[TBL] [Abstract][Full Text] [Related]
35. Benign Prostatic Hyperplasia and the Risk of Prostate Cancer and Bladder Cancer: A Meta-Analysis of Observational Studies.
Dai X; Fang X; Ma Y; Xianyu J
Medicine (Baltimore); 2016 May; 95(18):e3493. PubMed ID: 27149447
[TBL] [Abstract][Full Text] [Related]
36. [PSA testing, biopsy and cancer and benign prostate hyperplasia in France].
Tuppin P; Samson S; Fagot-Campagna A; Lukacs B; Alla F; Allemand H; Paccaud F; Thalabard JC; Vicaut E; Vidaud M; Millat B
Prog Urol; 2014 Jul; 24(9):572-80. PubMed ID: 24975792
[TBL] [Abstract][Full Text] [Related]
37. The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis.
Cindolo L; Fanizza C; Romero M; Pirozzi L; Autorino R; Berardinelli F; Schips L
World J Urol; 2013 Jun; 31(3):665-71. PubMed ID: 23239103
[TBL] [Abstract][Full Text] [Related]
38. The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis.
Weight CJ; Kim SP; Jacobson DJ; McGree ME; Boorjian SA; Thompson RH; Leibovich BC; Karnes RJ; St Sauver J
Eur Urol; 2013 Jun; 63(6):1021-7. PubMed ID: 23313032
[TBL] [Abstract][Full Text] [Related]
39. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
[TBL] [Abstract][Full Text] [Related]
40. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]